Reality Check on IBS-C
Market access for the treatment of irritable bowel syndrome with constipation (IBS-C) reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 40% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In September 2020, the FDA authorized an investigational new drug (IND) application from Seed Health to evaluate the impact of its DS-01, a broad spectrum probiotic, on gut microbiota of patients with irritable bowel syndrome
- Key Findings: This indication is dominated by pharmacy benefit coverage. An IBS-C diagnosis is required, and tests are issued to rule out other causes of constipation
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.